{
    "title": "Biogen dips as strategy post Alzheimer's setback fails to impress",
    "url": "https://www.dailymail.co.uk/wires/reuters/article-6954701/Biogen-quarter-profit-rises-20-pct-Spinraza-strength.html",
    "date": "2019-04-24",
    "keywords": [
        "company",
        "growth",
        "biogen",
        "share",
        "drug",
        "percent",
        "tecfidera",
        "quarter",
        "joseph",
        "manojna",
        "maddipatla",
        "development",
        "discontinuation",
        "analyst",
        "spinraza",
        "revenue",
        "inc",
        "beat",
        "street",
        "profit",
        "investor",
        "blockbuster",
        "lead",
        "face",
        "term",
        "business",
        "void",
        "call",
        "pipeline",
        "position",
        "latestage",
        "plan",
        "executive",
        "officer",
        "michel",
        "vounatsos",
        "path",
        "theyre",
        "companys",
        "driver",
        "atrophy",
        "treatment",
        "disease",
        "difficulty",
        "death",
        "competition",
        "novartis",
        "zolgensma",
        "consensus",
        "patent",
        "market",
        "reduction",
        "operating",
        "year",
        "aducanumab",
        "management",
        "rest",
        "capital",
        "geoffrey",
        "income",
        "attributable",
        "httpsbitly2l1ulkl",
        "basis",
        "morning",
        "trading",
        "reporting",
        "saumya",
        "sibi",
        "bengaluru",
        "editing",
        "dasgupta",
        "kuber"
    ],
    "category": [
        "wires",
        "reuters"
    ]
}